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Abstract
In the field of cardio-thoracic surgery, valve function is monitored over time after
surgery. The motivation for our research comes from a study which includes patients
who received a human tissue valve in the aortic position. These patients are followed
prospectively over time by standardized echocardiographic assessment of valve function.
Loss of follow-up could be caused by valve intervention or the death of the patient. One
of the main characteristics of the human valve is that its durability is limited. Therefore,
it is of interest to obtain a prognostic model in order for the physicians to scan trends in
valve function over time and plan their next intervention, accounting for the
characteristics of the data.
Several authors have focused on deriving predictions under the standard joint
modeling of longitudinal and survival data framework that assumes a constant effect for
the coefficient that links the longitudinal and survival outcomes. However, in our case
this may be a restrictive assumption. Since the valve degenerates, the association
between the biomarker with survival may change over time.
To improve dynamic predictions we propose a Bayesian joint model that allows a
time-varying coefficient to link the longitudinal and the survival processes, using
P-splines. We evaluate the performance of the model in terms of discrimination and
calibration, while accounting for censoring.
KEY WORDS: Joint model, longitudinal outcome, survival outcome, P-splines,
discrimination, calibration
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1 Introduction
In the field of cardio-thoracic surgery, valve function is monitored periodically over time
after heart valve surgery. Aortic gradient (AG) (mmHg) is one of the continuous
echocardiographic markers that measures valve (dys)function, where high values indicate
a worsening of the patient’s condition. Specifically, it measures aortic stenosis which
occurs when the opening of the aortic valve located between the left ventricle of the
heart and the aorta is narrowed. During the follow-up period after surgery, patients may
require an intervention or may die. The motivation of this research comes from a study,
conducted in the Erasmus University Medical Center, which includes all patients who
received a human tissue valve allograft in the aortic position in the Department of
Cardio-Thoracic Surgery (Bekkers et al., 2011). In total 296 patients who survived aortic
valve or root replacement with an allograft valve were followed over time. Specifically,
echocardiographic examinations were scheduled at six months, one year postoperatively
and biennially thereafter. During follow-up, 161 (54%) patients either died or required a
reoperation on the same valve. A total of 1669 echocardiographic measurements of AG
were performed. The median number of visits is six and the median years of follow up is
9.3. One of the characteristics of human valves is that their durability is limited. Hence,
it is important for the physicians to have a prognostic tool in order to carefully monitor
trends in valve function over time and plan a future re-intervention.
Joint modeling of longitudinal and survival data is a popular framework to analyze
data including repeated measurements and time-to-event outcomes appropriately
(Tsiatis and Davidian, 2004; Rizopoulos, 2012; Andrinopoulou et al., 2012;
Rizopoulos et al., 2015). The idea behind these models is that the longitudinal and the
survival processes share common random effects, inducing correlation between the two
processes. Specifically, we construct a mixed-effects model to describe the evolution over
time for the longitudinal outcome, and use these estimated evolutions as a
time-dependent covariate in a survival model. Several authors have focused on deriving
predictions under joint modeling of longitudinal and survival data framework
(Taylor, Yu, and Sandler, 2005; Garre et al., 2008; Yu, Taylor, and Sandler, 2008;
Proust-Lima and Taylor, 2009; Rizopoulos, 2011; Andrinopoulou et al., 2015a). To
improve the fit and the predictive accuracy of joint models, previous work allowed the
inclusion of multiple longitudinal outcomes and investigated the selection of the optional
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functional form (Rizopoulos, 2011; Rizopoulos et al., 2014; Andrinopoulou et al., 2015b;
Andrinopoulou and Rizopoulos, 2016). A common feature of all aforementioned models
and previous work published on the motivating data is that the parameters that
measure the strength of the association between the longitudinal and survival outcome
were assumed to be constant in time. However, the heart valve degenerates, therefore it
is natural and biologically more desirable to assume that the effect of AG is changing
over time. To investigate that, we performed a preliminary analysis assuming a
time-dependent Cox model for the composite event death/reoperation including as
predictors the square root of AG (SAG), a transformation that was explored in previous
work (Andrinopoulou et al., 2014), and gender. Figure 1 shows the smoothed scatterplot
of the Schoenfeld residuals from this Cox model versus time. These residuals are
typically used to investigate the proportional hazards assumption, and for the SAG they
show an increasing trend indicating violation of a constant-effect assumption.
Even though the consideration of time-varying coefficients has been extensively
studied in the general context of survival analysis using polynomials and B-splines
(Nan et al., 2005; Perperoglou, 2014), relatively little work has been done on joint
models with time-varying coefficients (Song and Wang, 2008). To our knowledge, no
work has been done to evaluate whether such time-varying coefficients may improve the
accuracy of individualized predictions within the framework of joint models. The idea
behind the time-varying coefficient models is to include interactions of the covariates
with an appropriate pre-defined time function. To enhance the predictive performance of
the joint model, we assume a time-varying effect of SAG using P-splines. Specifically, it
is approximated by a polynomial spline written in terms of a linear combination of
B-spline basis functions (Eliers and Marx, 1996; Lang and Brezger, 2004;
Eliers, Marx, and Durba´n, 2015). To overcome the problem of the large number of
parameters and to stabilize the predictions, a penalty is applied to the coefficients. To
facilitate flexible modeling of the survival outcome, we use P-splines also for the
logarithm of the baseline hazard. To evaluate the derived predictions we present
extensions of classic measures of predictive ability, such as discrimination and
calibration, in the time-dependent setting while accounting for censoring.
The rest of the paper is organized as follows. Section 2 describes the formulation of
the joint model. Section 3 presents the Bayesian estimation. Section 4 presents measures
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to assess the predictive performance of the model. Section 5 shows the results for the
cardio data analysis, while Section 6 contains simulation studies. Finally, in Section 7 we
close with a discussion.
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Figure 1: Time-varying coefficient of the SAG, using the Schoenfeld residuals. The solid line
represents the mean estimate while the dotted lines the corresponding confidence interval. The
dashed grey line represents the coefficient of the SAG.
2 Joint Model Definition
We let T∗i denote the true failure time for the i-th individual (i = 1, . . . , n), and Ci the
censoring time. Moreover, Ti = min(T
∗
i , Ci) denotes the observed failure time and
δi = {0, 1} is the event indicator where zero indicates censoring. We let yi denote the
longitudinal response obtained at different time points tij > 0, (j = 1, . . . , ni). To
describe the subject-specific evolution over time of the continuous longitudinal outcome
SAG, we use a mixed-effects model. In particular, we postulate
yi(t) = ηi(t) + ǫi = x
⊤
i (t)β + z
⊤
i (t)bi + ǫi(t),
where xi(t) denotes the design vector for the fixed effects regression coefficients β and
zi(t) the design vector for the random effects bi. Moreover, ǫi(t) ∼ N(0, σ). For the
corresponding random effects, we assume a multivariate normal distribution, namely
bi ∼ Nb(0,Σ
2
b).
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We postulate a varying-coefficient joint model (VCJM) for the relationship between
the survival and the longitudinal outcome. Specifically, we have
hi(t,θs) = h0(t) exp[γ
⊤wi + f{λ(t),Hi(t)}],
where θs is the parameter vector for the survival outcomes, wi is a vector of baseline
covariates with a corresponding vector of regression coefficients γ, γh0 is the vector of
the baseline hazard coefficient and Hi(t) = {ηi(ζ), 0 ≤ ζ < t} denotes the history of the
true unobserved longitudinal process up to time point t. The function f{λ(t),Hi(t)}
specifies which features of the longitudinal submodel are included in the relative risk
model (Rizopoulos and Ghosh, 2011; Rizopoulos, 2012). Previous work suggested that
not only the value of SAG but also other characteristics of the biomarker may have an
influence on the event of interest (Andrinopoulou et al., 2015b). Several specifications of
f(.) have been proposed in the literature (Rizopoulos and Ghosh, 2011). Some examples
are the following:
f{λ(t),Hi(t)} = λ(t)ηi(t),
f{λ(t),Hi(t)} = λ1(t)ηi(t) + λ2(t)
dηi(t)
dt ,
f{λ(t),Hi(t)} = λ(t)
∫ t
0 ηi(s)ds.
Specifically, f(.) postulates that the hazard of the event is associated with the underlying
value of the longitudinal outcome at a specific time point t, the value and the slope of
the longitudinal outcome at t, or the accumulated longitudinal process up to time t.
In the standard constant-coefficient joint model (CCJM), λ(t) is assumed to be
constant over time. For the VCJM, we model λ(t) flexibly assuming a smooth function.
Several approaches have been proposed for modelling and estimating smooth functions
such as B-splines. A problem that arises in such methods is the selection of the number
and position of the knots which has been a subject of much research. In this manuscript,
we adopt the P-splines approach for λ(t). The basic idea of P-splines is to use a
(relatively) high number of equally spaced knots. To obtain sufficient smoothness of the
fitted curves and to avoid overfitting, a roughness penalty based on differences of
adjacent B-spline coefficients is applied (Eliers and Marx, 1996). In particular, we take
λ(t) =
L∑
ℓ=1
αℓBℓ(t),
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where αℓ is a set of parameters that capture the strength of association between the
longitudinal and survival outcomes and Bℓ(t) denotes the ℓ-th basis function of a
B-spline. To further facilitate improving the derived predictions from the joint model,
we model the baseline hazard with the same P-splines approach. Specifically,
log{h0(t)} =
U∑
u=1
γh0,uBu(t),
where γh0,u are the coefficients of the baseline hazard and Bu(t) denotes the u-th basis
function of a B-spline.
3 Bayesian Estimation
We employ a Bayesian approach where inference is based on the posterior of the model.
In particular, we use Markov chain Monte Carlo (MCMC) methods to estimate the
parameters of the VCJM. The likelihood of the model is derived under the assumption
that the longitudinal and survival processes are independent given the random effects
(Rizopoulos, 2012). Moreover, the longitudinal responses of each subject are assumed
independent given the random effects. The posterior distribution is written as
p(θ | yi, Ti, δi) ∝
ni∏
j=1
p(yij | bi,θy)p{Ti, δi | ηi(Ti),θs}p(bi | θy)p(θy)p(θs),
where θ = (θ⊤s ,θ
⊤
y )
⊤ is the parameter vector for the survival and the longitudinal
outcomes respectively. The likelihood contribution of the longitudinal and survival
model together with the formulation of the deviance information criterion (DIC) are
given in the Appendix.
3.1 Bayesian P-splines
The Bayesian P-splines approach was first introduced by Lang and Brezger (2004). In
our case, the smoothness of functions λ(t) and h0(t) is controlled by the following priors
for the coefficient that links the longitudinal and the survival outcomes α and the
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coefficient of the baseline hazard γh0 :
α | τα ∼ NL(0, ταMα) and τα ∼ Gamma(c1, c2),
γh0 | τγh0 ∼ NU (0, τγh0Mγh0 ) and τγh0 ∼ Gamma(f1, f2),
where Mα, M γh0 are the penalty matrices. In particular,
Mα =Mγh0 = D
⊤
r Dr + 10
−6I, where Dr is a r-th order difference matrix. The scaled
identity matrix I ensures a positive define variance-covariance matrix. As described in
the literature (Reinsch, 1967; Eliers and Marx, 1996), a common choice for the penalty
matrices is to assume a second order penalty. The amount of smoothness is controlled
by the variance parameters τγh0 and τα, where hyperpriors are assigned. A usual
recommendation is to set c1 and f1 equal to 1 and c2 and f2 equal to a small number.
Alternative specifications of these hyperpriors can be found in Jullion and Lambert
(2007).
4 Measuring Predictive Performance
As motivated in Section 1, it is important for physicians to have a prognostic tool for
planning next interventions. To assess the predictive performance of the VCJM and to
compare it to the CCJM, we focus on discrimination and calibration. Specifically,
discrimination is how well can the model discriminate between patients who will
experience the event from patients who will not (Pencina et al., 2008), whereas
calibration is how well the model predicts the observed event rates
(Schemper and Henderson, 2000).
4.1 Discrimination
A key feature of our model is to distinguish between patients who are going to die or
require a reoperation within a specific time frame from patients who will not. In
particular, for a future patient l with SAG measurements y˜l up to time point t, we are
interested in investigating whether he will die or require a reoperation in the
medically-relevant time frame (t, t+∆t] within which the physician could intervene to
improve survival. The survival/intervention-free probability of patient l within this
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interval is,
πl(t,∆t) = Pr(T
∗
l ≥ t+∆t | T
∗
l > t, y˜l(t),Dn),
where Dn = {Ti, δi,yi, i = 1, . . . , n} denotes the sample on which the joint model was
fitted. For the calculation of sensitivity and specificity, we have πl(t,∆t) ≤ c if subject l
died or required a reoperation and πl(t,∆t) ≥ c if he did not experience
death/reoperation, for a specific c ∈ [0, 1]. In particular, we can define sensitivity and
specificity as
Pr{πl(t,∆t) ≤ c | T
∗
l ∈ (t, t+∆t]} and Pr{πl(t,∆t) > c | T
∗
l > t+∆t},
respectively. Using the area under the receiver operating characteristic curve (AUC) we
can assess the discriminative capability of the model. In particular, given a randomly
chosen pair of patients (l1, l2), we have
AUC(t,∆t) = Pr[πl1(t,∆t) < πl2(t,∆t) | {T
∗
l1 ∈ (t, t+∆t]} ∩ {T
∗
l2 > t+∆t}].
If patient l1 experiences death/reoperation within the relevant time frame whereas
patient l2 does not, then we would expect the VCJM to assign higher
survival/intervention-free probability during the period (t, t+∆t] for the patient that
did not experience death/reoperation. In the cardio data set, the values of
time-to-death/reoperation are not fully observed for all patients. To account for this,
the estimation of AUC(t,∆t) is based on the following decomposition
ÂUC(t,∆t) =
4∑
w=1
ÂUCw(t,∆t),
which include the following pairs of patients
Ω
(1)
l1l2
(t) = [{Tl1 ∈ (t, t+∆t]} ∩ {δl1 = 1}] ∩ {Tl2 > t+∆t},
Ω
(2)
l1l2
(t) = [{Tl1 ∈ (t, t+∆t]} ∩ {δl1 = 0}] ∩ {Tl2 > t+∆t},
Ω
(3)
l1l2
(t) = [{Tl1 ∈ (t, t+∆t]} ∩ {δl1 = 1}] ∩ [{Tl1 < Tl2 ≤ t+∆t} ∩ {δl2 = 0}],
Ω
(4)
l1l2
(t) = [{Tl1 ∈ (t, t+∆t]} ∩ {δl1 = 0}] ∩ [{Tl1 < Tl2 ≤ t+∆t} ∩ {δl2 = 0}].
ÂUC1(t,∆t) includes the pairs of patients who are comparable Ω
(1)
l1l2
(t) and∑4
w=2 ÂUCw(t,∆t) the pairs of patients who due to censoring cannot be compared
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{Ω
(w)
l1l2
(t), w = 2, 3, 4}. Then, with I(.) the indicator function
ÂUCw(t,∆t) =
∑n
l1=1
∑n
l2=1;l2 6=l1
I{πˆl1(t,∆t) < πˆl2(t,∆t)} × I{Ω
(w)
l1l2
(t)} × Kˆw∑n
l1=1
∑n
l2=1;l2 6=l1
I{Ω
(w)
l1l2
(t)} × Kˆw
,
which is the proportion of concordant subjects out of the set of comparable subjects at
time t. Specifically, if in a randomly selected pair of patients, the one with the higher
event probability experiences the event and the one with the lower probability does not
experience the event, then this pair is said to be a concordant pair. For w = 1, we have
Kˆ2 = 1 because the pairs of patients are comparable. For w = 2, 3, 4, the ÂUCw(t,∆t)
are weighted with the probability that the concordant subjects are comparable. In
particular, Kˆ2 = 1− πˆl1(t,∆t), Kˆ3 = πˆl2(t,∆t) and Kˆ4 = {1− πˆl1(t,∆t)} × πˆl2(t,∆t)
4.2 Calibration
To assess the accuracy of the model, we use the prediction error (PE). Using all
available information for a particular patient l, we are interested in comparing the
predicted probability of survival/intervention-free of this patient to the observed truth:
PE(t,∆t) = E[{Nl(t+∆t)− πl(t,∆t)}
2]
where Nl(t) = I(T
∗
l > t) is the event status at time t. To account for censoring, the
following estimate has been proposed by Henderson et al. (2002):
P̂E(t,∆t) =
{R(t)}−1
∑
l:Tl≥t
{
I(Tl > t+∆t){1− πˆl(t,∆t)}
2 + δlI(Tl < t+∆t){0− πˆl(t,∆t)}
2+
(1− δl)I(Tl < t+∆t)
[
πˆl(Tl,∆t){1− πˆl(t,∆t)}
2 + {1− πˆl(Tl,∆t)}{0 − πˆl(t,∆t)}
2
]}
where R(t) denotes the number of subjects at risk at t. The term
I(Tl > t+∆t){1− πˆl(t,∆t)}
2 refers to patients who were alive after t+∆t and
δlI(Tl < t+∆t){0− πˆl(t,∆t)}
2 to patients who died before t+∆t. The remaining term
refers to patients who were censored in the interval [t, t+∆t].
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5 Analysis of the Cardio Data Set
In this section we present the analysis of the cardio data introduced in Section 1. Our
primary focus is to investigate the association between SAG with
time-to-death/reoperation. In Figure A.1, the evolution of the SAG for 12 randomly
selected patients is presented, where it is shown that most of these patients have
non-linear profiles. Therefore, we assumed a linear mixed-effects submodel including
natural cubic splines for time. The DIC criterion indicated that the model assuming one
internal knot at 5.02 years (corresponding to 50% of the observed follow-up times) in
both the fixed- and random-effects parts had a better fit. Furthermore, we corrected for
gender. The mixed-effects submodel for the SAG is
yi(t) = ηi(t) + ǫi(t) = β0 + β1gi +
2∑
v=1
βv+1ns(t; v) + b0i +
2∑
v=1
bvins(t; v) + ǫi(t),
where yi(t) are the measurements of SAG, ns(.) denotes the natural cubic splines,
ǫi(t) ∼ N(0, σ) and bi ∼ Nb(0,Σ
2
b).
To investigate the association between SAG and survival, we postulated the VCJM.
Motivated by previous work (Andrinopoulou et al., 2015b), where different features of
the SAG were found to have an influence on survival, we assumed the value and the
slope of the longitudinal outcome to be associated with death/reoperation. Furthermore,
we corrected for gender. Specifically, the survival submodel takes the form
hi(t,θs) = exp
{∑U
u=1 γh0,uBu(t)
}
exp
{
γgi + λ1(t)ηi(t) + λ2(t)
dηi(t)
dt
}
= exp
{∑U
u=1 γh0,uBu(t)
}
exp
{
γgi +
∑L
ℓ=1 α1ℓBℓ(t)ηi(t) +
∑L
ℓ=1 α2ℓBℓ(t)
dηi(t)
dt
}
,
where α1ℓ and α2ℓ are the coefficients that link the longitudinal and survival processes, γ
is the coefficient for gender and γh0,ℓ are the baseline hazard coefficients. We assumed in
both cases quadratic B-splines basis Bℓ(t) = Bu(t) with 8 equally distance internal knots
ranging from zero until 20.1 years.
As described in Section 3, for the P-splines approach we assumed normal priors for
the time-varying coefficients α = {α1,α2} and the baseline hazard coefficients γh0 and
gamma hyperpriors for τα and τγh0 where we took c1 = f1 = 1 and c2 = f2 = 0.005. For
the rest of the parameters standard noninformative priors were used. For the coefficients
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of the longitudinal outcome β and the survival coefficient γ normal priors were taken
with mean zero and large variance. For the variance-covariance matrix of the random
effects Σb we assumed inverse Wishart prior with an identity scale matrix and degrees of
freedom equal to the total number of the random effects. For the precision parameter of
the longitudinal outcome a gamma prior was taken with parameters that were based on
the separate analysis of the outcome. We ran the MCMC using three chains with
150,000 iterations, 50,000 burn-in and 2 thinning.
In Figure 2 we present the mean estimates and the credible intervals of the estimated
λ(t) for the value and the slope association parameters, respectively. The grey solid lines
represent the coefficient when CCJM was assumed. The CCJM takes the form,
hi(t,θs) = exp
{
U∑
u=1
γh0,uBu(t)
}
exp
{
γgi + α1ηi(t) + α2
dηi(t)
dt
}
,
where we use P-splines for the baseline hazard for a fair comparison. We observe that
the effect of the SAG on survival seems to slightly increase over time, however this effect
is not strong. The effect of the slope of SAG on survival appears to increase linearly
with time. Specifically, at the beginning of the study (t = 5), for patients having the
same gender and level of SAG, the log hazard ratio for one mmHg increase in the
current slope of the SAG is 3.4. However, at the end of the study (t = 15) this effect
increases to 7.4. Further results of the models including the posterior estimates, DIC
and Gelman-Rubin’s diagnostic are presented in Tables B.1 and B.2 and a discussion
(Appendix). In Figure A.2, we present prediction plots for a 46 year old male. Every
time the patient visits the hospital his survival/intervention-free probabilities are
updated. Specifically, five years after his first visit his survival/intervention-free
probability is 0.7, while five years after his last visit this probability is 0.3. The
evolution of the SAG for the specific patient is presented in Figure A.3.
To investigate whether the proposed VCJM improves dynamic predictions, we
compared the VCJM with the CCJM based on the AUC(t,∆t) and PE(t,∆t) measures
introduced in Section 4. Corrected estimates of these measures were obtained using an
internal validation procedure. We performed a 5-fold cross-validation by splitting our
data set in five subsets, fitting each time the model in four of the subsets and calculating
the accuracy measures in the subset that was excluded. This cross-validation procedure
was replicated 100 times. The calculation of AUC(t,∆t) and PE(t,∆t) was performed
11
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Figure 2: With black lines the mean estimates (solid line) and the credible intervals (dashed
lines) of λ1(t) and λ2(t) functions corresponding to the value and slope association parameters
are presented. The grey solid lines represent the mean estimates of the CCJM.
for the follow-up times {t = 5.5, 7.5, 9.5} whereas ∆t = 2. The results are presented in
Figure 3 where boxplots of 100 cross validations are shown. We obtained better
discriminative capability (AUC) and predictive accuracy (PE) from the VCJM model
compared to the CCJM in all cases. Specifically, we observe most of the time higher
AUC values and lower PE values for the VCJM. These differences seem to be more
profound for later follow-up times.
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6 Simulation study
6.1 Design
We performed a series of simulations to evaluate the performance of the VCJM. We
simulated 400 patients with maximum number of repeated measurements equal to 10.
We assumed one longitudinal and one survival outcome as in the analysis of the cardio
data set. For the continuous longitudinal outcome, we investigated the following linear
mixed-effects model
yi(t) = ηi(t) + ǫi(t) = β0 + β1gi + β2t+ b0i + b1it+ ǫi(t),
where ǫi ∼ N(0, σ
2
y) and b = (b0i, b1i) ∼ N2(0,Σ
2
b). For simplicity, we adopted a linear
effect of time for both the fixed and the random part, and corrected for gender. Time t
was simulated from a uniform distribution between zero and 19.5. For the survival part,
we investigated the following scenarios.
For Scenario I, we postulated the following model:
hi(t) = h0(t) exp
{
γgi + λ(t)ηi(t)
}
= h0(t) exp
{
γgi +
∑L
ℓ=1 αℓBℓ(t)ηi(t)
}
,
where Bℓ(t) denotes the ℓ-th basis function of a B-spline where the knots were placed at
fixed time points. We assumed time-varying effect of the underlying value for the
association parameter and corrected for gender. The baseline risk was simulated from a
Weibull distribution h0(t) = ξt
ξ−1. For the simulation of the censoring times, an
exponential censoring distribution was chosen with mean µc, so that the censoring rate
was between 40% and 60%. Scenario Ia assumed a linear evolution for λ(t), while
Scenario Ib a non-linear evolution.
For Scenario II, the survival submodel takes the form,
hi(t) = h0(t) exp
{
γgi + αηi(t)
}
,
where a constant effect for the α coefficient was assumed.
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Finally, for Scenario IIIa and Scenario IIIb, the survival submodel takes the form,
hi(t) = h0(t) exp
{
γgi + α1 + α2ηi(t) + α3η
2
i (t)
}
,
and hi(t) = h0(t) exp
{
γgi + α1 + α2ηi(t) + α3η
2
i (t) + α4η
3
i (t) + α5η
4
i (t)
}
,
respectively. In this case, we assumed polynomial effects for the association parameters.
We simulated 200 data sets per scenario. More details are presented in Table B.3.
6.2 Analysis and Results
To evaluate the performance of the proposed model, we fit the VCJM and the CCJM
with the same specification as the one presented in Section 6.1. To mimic the analysis of
the cardio data set, the joint models were fitted using P-splines for the baseline hazard,
rather than the Weibull one. Figure A.4 and A.5, illustrate the true and estimated λ(t)
function when simulating from the linear Scenario Ia (left panel) and the non-linear
Scenario Ib (right panel) and when fitting the VCJM. In particular, in Figure A.4 we
assumed 8 internal knots for the simulation and the fitting part while in Figure A.5 we
assumed 20. Figure A.6 illustrates the true and estimated λ(t) function for Scenario II
when fitting the VCJM assuming 8 internal knots. Figures A.7 and A.8 present the
results when simulating for Scenario IIIa and Scenario IIIb respectively and when fitting
the VCJM with 8 internal knots. Overall our model successfully recovers the true λ(t).
The reason for observing greater variability at t < 5 and t > 15 is that relatively few
events are observed in these regions.
To further evaluate whether the VCJM produces predictions of better quality than
the CCJM, we performed an external validation procedure. For each simulated data set
from scenarios Ia, Ib and II, we randomly excluded 200 patients. Using the remaining
patients, we fitted the VCJM and the CCJM and computed the AUC(t,∆t) and
PE(t,∆t) for the 200 patients that were initially excluded. These measures were
calculated at follow-up times {t = 5.5, 7.5, 9.5} using ∆t = 2. Figures 4 and 5 present
boxplots with the results under Scenarios Ia and Ib, respectively. It can be seen that,
overall, the VCJM performs better than the CCJM. Most of the time we observe a
higher AUC value and a lower PE value for the VCJM. Smaller differences are obtained
for Scenario Ib for the AUC at t = 5.5 and the PE at t = 9.5. This is explained by the
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fact that not enough events were observed at the specific time periods. Figure 6, which
presents boxplots for Scenario II, suggests that the VCJM provides accurate predictions
even if the data is generated with a constant effect for the coefficient that links the
longitudinal and survival outcomes. In all cases, we obtain AUC and PE values that are
similar in both the VCJM and the CCJM.
0.
10
0.
15
0.
20
VCJM CCJM
t = 5.5 − 7.5
PE
0.
15
0.
20
0.
25
VCJM CCJM
t = 7.5 − 9.5
PE
0.
10
0.
20
0.
30
VCJM CCJM
t = 9.5 − 11.5
PE
0.
6
0.
7
0.
8
0.
9
VCJM CCJM
t = 5.5 − 7.5
AUC
0.
75
0.
85
0.
95
VCJM CCJM
t = 7.5 − 9.5
AUC
0.
7
0.
8
0.
9
1.
0
VCJM CCJM
t = 9.5 − 11.5
AUC
Figure 4: Boxplots of the AUC and PE measurements when assuming the VCJM and the
CCJM at different time points with ∆t = 2. For the simulation of the data scenario Ia was
used - External validation.
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Figure 5: Boxplots of the AUC and PE measurements when assuming the VCJM and the
CCJM at different time points with ∆t = 2. For the simulation of the data scenario Ib was
used - External validation.
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Figure 6: Boxplots of the AUC and PE measurements when assuming the VCJM and the
CCJM at different time points with ∆t = 2. For the simulation of the data scenario II was
used - External validation.
7 Discussion
Motivated by the fact that the human tissue valves degenerate and hence the effect of
SAG on survival could change over time, we developed a VCJM using P-splines. We
used P-splines for the logarithm of the baseline hazard. We showed that even when the
data is generated with a constant effect for the coefficient that links the longitudinal and
survival outcome, the VCJM performs equal or better than the CCJM. In this paper we
followed the Bayesian framework and therefore, extensions to more complex situations
are comparably easy. A further advantage of the Bayesian approach, is that it allows us
to automatically estimate the smoothing parameter in the P-splines approach by
assigning a prior to it.
Further extensions to improve the VCJM can be considered for future work. In this
paper we used only one longitudinal and one survival outcome. Extension to multiple
longitudinal outcomes might be useful since other longitudinal outcomes that are related
to the heart value may have an influence on survival. Finally, death and reoperation are
competing risks and therefore a competing risk survival submodel would be more
appropriate.
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Appendix
Likelihood and DIC
The likelihood contribution of the longitudinal submodel takes the form
p(yij | θy, bi) = (2πσ)
−1/2 exp
[
−
(yij − xij
⊤β − zij
⊤bi)
2
2σ2
]
,
where θy are the parameters of the longitudinal submodel. The likelihood contribution
of the survival submodel is given by
p{Ti, δi | ηi(Ti),θs} =
exp
[ Q∑
q=1
γh0,qBq(Ti,ν) + γ
⊤wi + f{
L∑
l=1
αlBl(Ti), ηi(Ti)}
]I(δi=1)
×
exp
{
− exp (γ⊤wi)
∫ Ti
0
exp
[ Q∑
q=1
γh0k ,qBq(s,ν) + f{
L∑
l=1
αlBl(s), ηi(s)}
]
ds
}
,
where θs are the parameters of the survival submodel. The integral of the survival
function does not have a closed-form solution, and thus a numerical method must be
employed for this evaluation. To approximate this integral we used the Gaussian
quadrature rule and we assume a 15-point Gauss-Kronrod rule.
The joint likelihood function is written as
p(yi, Ti, δi | θ, bi) =
ni∏
j=1
p(yij | bi,θy)p{Ti, δi | ηi(Ti),θs}p(bi | θy),
where θ = (θ⊤s ,θ
⊤
y )
⊤ and
p(bi | θy) = [2π det(D)]
−1/2 exp
(
−
b⊤i D
−1bi
2
)
.
We use the DIC constructed from the conditional distribution where the random
effects are treated as parameters since it facilitates computations. In particular, the DIC
takes the form
DIC = pD + D¯,
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where
pD = D¯ −D(θ¯, b¯),
D¯ = E{D[θ(g), b(g)]},
D[θ(g), b(g)] = −2
n∑
i=1
log{p[yi, Ti, δi | θ
(g), b(g)]},
where b = b1, . . . , bn are the random effects, g = 1, . . . , G is the iteration of the sampler,
θ(g) and b(g) denote the parameter samples at the gth iteration and θ¯ and b¯ represent
the means of the posterior samples. The model with the smaller DIC value represents
the model with the best fit.
Discussion of the data results
In Table B.1 and B.2 we present the posterior means, the standard errors, the 95%
credible intervals and the Gelman-Rubin’s Rhat diagnostic of the VCJM and CCJM
respectively.
With regards to the VCJM, it can be seen that gender does not seem to be a strong
factor for the SAG. A nonlinear effect of time seems to capture the evolution of SAG.
Furthermore, gender does not seem to have an influence on the survival outcome. The
results of the association parameters are difficult to interpret therefore plots were
created in the manuscript (Figure 2 in the main paper) where it can be seen that the
slope of the SAG on survival appears to increase linearly with time. The
Gelman-Rubin’s diagnostic (potential scale reduction factor) suggests that all the
parameters of the VCJM converged.
With regards to the CCJM, we found the same results for the longitudinal submodel
as in the VCJM. Moreover, gender does not seem to have an influence on the survival
outcome. The underlying value and slope of the SAG seem to have an effect on the
survival outcome. In particular, the log hazard is increased by 0.17, with 95% credible
interval [0.03, 0.30], for each unit increase in the current value of the SAG. Furthermore,
the log hazard is increased by 2.98, with 95% credible interval [1.45, 4.75], for each unit
increase in the current slope of the SAG. The Gelman-Rubin’s diagnostic suggests that
all the parameters of the CCJM converged.
The DIC values indicate that the VCJM provides a better fit of the data compared
21
to the CCJM.
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Figure A.1: Profile of the SAG for 12 randomly selected patients.
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Figure A.2: Dynamic survival/intervention-free predictions for patient 10. The vertical dotted
lines represent the time point of the last SAG measurement. On the left side, the fitted
longitudinal trajectory is presented. On the right side, the solid line represents the mean
estimator of the predictions while the dashed lines the corresponding 95% confidence interval.
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Figure A.3: The SAG evolution for patient 10.
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Figure A.4: Simulation results assuming a time-varying effect (Scenario I) and 8 internal knots
when simulating and assuming the VCJM with the same knots when fitting the data: the left
panel corresponds to Scenario Ia (linear λ(t)) and the right panel to Scenario Ib (non-linear
λ(t)). The solid black lines denote the true λ(t) function, the dashed black lines the average
estimates of this function from the 200 data sets and the grey lines the estimates from each of
the 200 data sets.
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Figure A.5: Simulation results assuming a time-varying effect (Scenario I) and 20 internal knots
when simulating and assuming the VCJM with the same knots when fitting the data: the left
panel corresponds to Scenario Ia (linear λ(t)) and the right panel to Scenario Ib (non-linear
λ(t)). The solid black lines denote the true λ(t) function, the dashed black lines the average
estimates of this function from the 200 data sets and the grey lines the estimates from each of
the 200 data sets.
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Figure A.6: Simulation results assuming a constant effect (Scenario II) when simulating and
assuming the VCJM with 8 internal knots when fitting the data: The solid black lines denote
the true association parameter, the dashed black lines the average estimates of this function
from the 200 data sets and the grey lines the estimates from each of the 200 data sets.
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Figure A.7: Simulation results assuming a second degree polynomial for the time function of
the time-varying coefficient (Scenario IIIa) when simulating and assuming the VCJM with 8
internal knots when fitting the data: The solid black lines denote the true association parameter,
the dashed black lines the average estimates of this function from the 200 data sets and the
grey lines the estimates from each of the 200 data sets.
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Figure A.8: Simulation results assuming a fourth degree polynomial for the time function of
the time-varying coefficient (Scenario IIIb) when simulating and assuming the VCJM with 8
internal knots when fitting the data: The solid black lines denote the true association parameter,
the dashed black lines the average estimates of this function from the 200 data sets and the
grey lines the estimates from each of the 200 data sets.
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B Tables
Table B.1: VCJM results: posterior means, standard errors, 95% credible intervals and Rubin
and Gelman-Rubin’s diagnostic. Rhat = potential scale reduction factor.
Mean SE 2.5% 97.5% Rhat
SAG
(intercept) 3.02 0.00 2.87 3.17 1.00
SexFemale 0.18 0.00 -0.07 0.44 1.00
ns(echotime, 2)1 3.83 0.01 3.29 4.38 1.00
ns(echotime, 2)2 3.42 0.01 2.77 4.12 1.00
Death/reoperation
SexFemale 0.01 0.00 -0.38 0.38 1.00
alpha value[1] -0.02 0.01 -0.58 0.52 1.00
alpha value[2] 0.02 0.01 -0.39 0.40 1.00
alpha value[3] 0.05 0.01 -0.24 0.33 1.00
alpha value[4] 0.08 0.00 -0.16 0.29 1.00
alpha value[5] 0.10 0.00 -0.12 0.28 1.00
alpha value[6] 0.13 0.00 -0.10 0.32 1.00
alpha value[7] 0.13 0.01 -0.12 0.35 1.00
alpha value[8] 0.15 0.01 -0.15 0.42 1.00
alpha value[9] 0.21 0.01 -0.17 0.59 1.00
alpha value[10] 0.29 0.01 -0.21 0.85 1.00
alpha slope[1] 0.78 0.05 -2.74 4.09 1.00
alpha slope[2] 1.95 0.04 -0.67 4.63 1.00
alpha slope[3] 3.11 0.04 0.91 5.67 1.00
alpha slope[4] 4.27 0.06 1.97 7.42 1.00
alpha slope[5] 5.42 0.08 2.60 9.59 1.00
alpha slope[6] 6.57 0.10 3.01 12.03 1.00
alpha slope[7] 7.71 0.12 3.30 14.52 1.00
alpha slope[8] 8.85 0.15 3.54 17.06 1.00
alpha slope[9] 9.99 0.17 3.68 19.59 1.00
alpha slope[10] 11.13 0.19 3.82 22.20 1.00
DIC 8829.617
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Table B.2: CCJM results: posterior means, standard errors, 95% credible intervals and Rubin
and Gelman-Rubin’s diagnostic. Rhat = potential scale reduction factor
Mean SE 2.5% 97.5% Rhat
SAG
(Intercept) 3.01 0.00 2.86 3.16 1.00
SexFemale 0.19 0.00 -0.07 0.44 1.00
ns(echotime, 2)1 3.81 0.01 3.31 4.33 1.00
ns(echotime, 2)2 3.29 0.01 2.65 4.01 1.00
Death/reoperation
SexFemale 0.01 0.00 -0.36 0.36 1.00
alpha value 0.17 0.00 0.03 0.30 1.00
alpha slope 2.98 0.02 1.45 4.75 1.00
DIC 8917.099
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Table B.3: Simulation scenarios.
Scenario β σy diag{Σb} ξ µc γ α
Ia
(Intercept) = 3.03 0.69 0.93 1.2 30 (Intercept) = -7.85 0.19
Females = 0.14 0.16 Females =-0.02 0.35
Time = 0.16 0.5
0.9
1.3
1.9
2.2
2.59
2.9
3.19
Ib
(Intercept) = 3.03 0.69 0.93 1.2 30 (Intercept) = -7.75 0.19
Females = 0.14 0.16 Females =-0.02 0.35
Time = 0.16 0.4
0.6
0.9
1
2.2
2.59
2.9
3.19
II
(Intercept) = 3.03 0.69 0.93 1.9 24 (Intercept) = -7.85 0.38
Females = 0.14 0.16 Females =-0.02
Time = 0.16
IIIa
(Intercept) = 3.02 0.69 0.93 1.7 12 (Intercept) = -5.75 -0.89
Females = 0.16 0.16 Females = 0.01 0.26
Time = 0.16 -0.01
IIIb
(Intercept) = 3.02 0.69 0.93 1.7 12 (Intercept) = -5.75 -1.33
Females = 0.16 0.16 Females = 0.01 0.75
Time = 0.16 -0.15
0.01
-0.0002
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